title: [New faces of acute rejection in 2008].
abstract: Along the time, the definition of acute rejection has been modified according to the successive Banff classifications, the use of C4d and the identification of anti- HLA antibodies. Both cellular and humoral acute rejection are nowadays considered to be different with regard to definition, pathogenesis and hence treatment. The Banffclassification remains a very useful tool to improve the precision of these definitions. The new technologies such as microarrays should help to identify new aspects of acute rejection.
authors: Université Paris Descartes & Service de Transplantation Rénale Adulte, Hôpital Necker, 149 rue de Sèvres, 75743 Paris cedex 15. christophe.legendre@nck.aphp.fr
authors: C
authors: C
authors: Legendre
mesh_terms: D000208:Acute Disease; D015415:Biomarkers / Q000097:blood*; D003167:Complement Activation / Q000276:immunology; D015935:Complement C4b; D006084:Graft Rejection / Q000276:immunology* / Q000473:pathology; D006085:Graft Survival / Q000276:immunology; D006680:HLA Antigens / Q000097:blood; D006801:Humans; D007155:Immunologic Factors / Q000097:blood; D007518:Isoantibodies / Q000097:blood; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology / Q000639:trends; D010446:Peptide Fragments / Q000097:blood; D011379:Prognosis; D014184:Transplantation, Homologous / Q000276:immunology
chemical_list: D015415:Biomarkers; D006680:HLA Antigens; D007155:Immunologic Factors; D007518:Isoantibodies; D010446:Peptide Fragments; D015935:Complement C4b; C032261:complement C4d